Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imipenem

FDA-approved product (powder, intravenous).

Registered studies
50+
Lab records
505
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Imipenem
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Endocarditis
  • Infection
  • Pneumonia
  • Sepsis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Carbapenems
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DH51

Repurposing investigation

Imipenem is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae96.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis31.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 44 of 77 lab records
  • E. coli: measured active in 86 of 94 lab records
  • K. pneumoniae: measured active in 247 of 334 lab records
Open Imipenem in ChEMBL Registered studies below
Show the latest 150 of 505 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imipenem with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella Pneumoniae

    NCT04229498 · start 2020-04

    Registered record
    Registry ID
    NCT04229498
    Conditions
    Bloodstream Infection
    Interventions
    Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-04
    Completion
    2021-11
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBloodstream Infection
    InterventionMonotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
    PhaseNot recorded
    Registry statusUnknown

  • Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

    NCT04310930 · start 2020-03-02

    Registered record
    Registry ID
    NCT04310930
    Conditions
    Pulmonary Disease Due to Mycobacteria (Diagnosis)
    Interventions
    Amikacin; Tigecycline; Imipenem; Cefoxitin; Azithromycin; Clarithromycin; Clofazimine; Ethambutol; Amikacin; Linezolid; co-trimoxazole; Doxycycline; Moxifloxacin; Bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2020-03-02
    Completion
    2030-06-30
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPulmonary Disease Due to Mycobacteria (Diagnosis)
    InterventionAmikacin; Tigecycline; Imipenem; Cefoxitin +11 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Management of an Imipenem-resistant Acinetobacter Baumannii Alert in a French University Hospital

    NCT06173440 · start 2020-01-01

    Registered record
    Registry ID
    NCT06173440
    Conditions
    Acinetobacter Baumannii
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2023-12
    Enrolment
    148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Baumannii
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

    NCT04208763 · start 2019-12-20

    Registered record
    Registry ID
    NCT04208763
    Conditions
    Spontaneous Bacterial Peritonitis
    Interventions
    Imipenem; Tigecycline; GMCSF; Colistin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-12-20
    Completion
    2021-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpontaneous Bacterial Peritonitis
    InterventionImipenem; Tigecycline; GMCSF; Colistin
    PhaseNot applicable
    Registry statusUnknown

  • In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients

    NCT04196608 · start 2019-11-01

    Registered record
    Registry ID
    NCT04196608
    Conditions
    Ceftolozane/Tazobactam; Imipenem/Relebactam; Hematology and Oncology
    Interventions
    Ceftolozane/tazobactam; imipenem- relebactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2019-11-01
    Completion
    2020-09-30
    Enrolment
    1,005

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCeftolozane/Tazobactam; Imipenem/Relebactam; Hematology and Oncology
    InterventionCeftolozane/tazobactam; imipenem- relebactam
    PhaseNot recorded
    Registry statusUnknown

  • Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

    NCT03894046 · start 2019-09-05

    Registered record
    Registry ID
    NCT03894046
    Conditions
    Acinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia; Colistin Resistant ABC
    Interventions
    Sulbactam; Durlobactam; Colistin; Imipenem/Cilastatin 500 mg/500 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-09-05
    Completion
    2021-07-26
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcinetobacter Baumannii-calcoaceticus Complex; Hospital-acquired Bacterial Pneumonia; Ventilator-associated Bacterial Pneumonia; Bacteremia +1 more
    InterventionSulbactam; Durlobactam; Colistin; Imipenem/Cilastatin 500 mg/500 mg
    PhasePhase 3
    Registry statusCompleted

  • PK/PD and Clinial Outcomes of Beta-lactams in ICU Patients

    NCT03858387 · start 2018-09-01

    Registered record
    Registry ID
    NCT03858387
    Conditions
    Critical Illness; Bacterial Infections
    Interventions
    Meropenem; Imipenem
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-09-01
    Completion
    2021-12-31
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness; Bacterial Infections
    InterventionMeropenem; Imipenem
    PhaseNot recorded
    Registry statusUnknown

  • Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

    NCT03625739 · start 2018-07-01

    Registered record
    Registry ID
    NCT03625739
    Conditions
    Tuberculosis
    Interventions
    anti-tuberculosis drug
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2018-07-01
    Completion
    2026-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    Interventionanti-tuberculosis drug
    PhaseNot recorded
    Registry statusRecruiting

  • The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients

    NCT03308214 · start 2018-03-18

    Registered record
    Registry ID
    NCT03308214
    Conditions
    Septic Shock
    Interventions
    Imipenem
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-03-18
    Completion
    2018-12-28
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionImipenem
    PhaseNot recorded
    Registry statusCompleted

  • Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis

    NCT03012360 · start 2018-02-08

    Registered record
    Registry ID
    NCT03012360
    Conditions
    Mechanical Ventilation Complication; Critical Illness
    Interventions
    ceftriaxone; ciprofloxacin; imipenem; linezolid; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2018-02-08
    Completion
    2024-07-07
    Enrolment
    103

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMechanical Ventilation Complication; Critical Illness
    Interventionceftriaxone; ciprofloxacin; imipenem; linezolid +1 more
    PhasePhase 4
    Registry statusTerminated

  • Second-generation Sequencing Guides the Treatment of Severe Pneumonia

    NCT03884881 · start 2018-01-01

    Registered record
    Registry ID
    NCT03884881
    Conditions
    Pneumonia; Metagenomic Next Generation Sequencing
    Interventions
    metagenomic next generation sequencing; Conventional pathogen detection; Meropenem，Imipenem，Caspofene，Osstat
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2018-01-01
    Completion
    2019-12-01
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Metagenomic Next Generation Sequencing
    Interventionmetagenomic next generation sequencing; Conventional pathogen detection; Meropenem，Imipenem，Caspofene，Osstat
    PhaseNot applicable
    Registry statusUnknown

  • Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases

    NCT03113344 · start 2017-06-21

    Registered record
    Registry ID
    NCT03113344
    Conditions
    Children; Infection
    Interventions
    cephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-06-21
    Completion
    2025-12-31
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildren; Infection
    Interventioncephalosporins,penicillins,macrolides,carbapenems and antiviral drugs
    PhaseNot recorded
    Registry statusUnknown

  • The Individualized M(X) Drug-resistant TB Treatment Strategy Study

    NCT03237182 · start 2017-06-14

    Registered record
    Registry ID
    NCT03237182
    Conditions
    Tuberculosis, Multidrug-Resistant
    Interventions
    Individualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2017-06-14
    Completion
    2022-12-19
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis, Multidrug-Resistant
    InterventionIndividualized TB treatment with multiple drugs; Standardized TB treatment with multiple drugs
    PhasePhase 4
    Registry statusTerminated

  • Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens

    NCT03159078 · start 2017-05-25

    Registered record
    Registry ID
    NCT03159078
    Conditions
    Trauma; Resistant Infection; Critical Illness
    Interventions
    Polymyxin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-05-25
    Completion
    2019-12-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrauma; Resistant Infection; Critical Illness
    InterventionPolymyxin B
    PhasePhase 3
    Registry statusUnknown

  • Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

    NCT02474706 · start 2016-03

    Registered record
    Registry ID
    NCT02474706
    Conditions
    Urinary Tract Infections
    Interventions
    Cefoxitin; imipenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-03
    Completion
    2017-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Tract Infections
    InterventionCefoxitin; imipenem
    PhasePhase 4
    Registry statusTerminated